Third View Private Wealth LLC Invests $4.06 Million in Thermo Fisher Scientific Inc. $TMO

Key Points

• Third View Private Wealth LLC opened a new position in Thermo Fisher (NYSE:TMO) in Q4, buying 7,001 shares worth about $4.06 million according to the firm's Form 13F filing.
• Thermo Fisher beat Q4 expectations with $6.57 EPS and $12.22 billion in revenue, and several analysts raised price targets, leaving the consensus rating at a "Moderate Buy" with a $632.50 average target.
• The company raised its quarterly dividend to $0.47 (annualized $1.88, ~0.4% yield), while insiders including CEO Marc N. Casper recently sold shares (5,000 shares for roughly $2.56 million), modestly trimming their holdings.

Third View Private Wealth LLC acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,001 shares of the medical research company's stock, valued at approximately $4,057,000.

Several other large investors also recently made changes to their positions in the stock. Cornerstone Investment Partners LLC bought a new position in Thermo Fisher Scientific in the third quarter valued at $41,393,000. Weaver Capital Management LLC bought a new position in Thermo Fisher Scientific in the third quarter valued at $506,000. Mackenzie Financial Corp grew its position in Thermo Fisher Scientific by 29.4% in the third quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company's stock valued at $134,130,000 after purchasing an additional 62,790 shares in the last quarter. VELA Investment Management LLC grew its position in Thermo Fisher Scientific by 65.5% in the third quarter. VELA Investment Management LLC now owns 9,305 shares of the medical research company's stock valued at $4,513,000 after purchasing an additional 3,683 shares in the last quarter. Finally, NEOS Investment Management LLC grew its position in Thermo Fisher Scientific by 28.6% in the third quarter. NEOS Investment Management LLC now owns 51,364 shares of the medical research company's stock valued at $24,913,000 after purchasing an additional 11,415 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the sale, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. The trade was a 3.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $541.20, for a total transaction of $216,480.00. Following the completion of the sale, the executive vice president owned 20,752 shares of the company's stock, valued at $11,230,982.40. This trade represents a 1.89% decrease in their position. The SEC filing for this sale provides additional information. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $514.75 on Tuesday. The firm has a 50-day moving average of $503.98 and a 200-day moving average of $549.81. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 1.89. The stock has a market cap of $191.29 billion, a PE ratio of 29.02, a P/E/G ratio of 2.66 and a beta of 0.97. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.45 by $0.12. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The company had revenue of $12.22 billion during the quarter, compared to analysts' expectations of $11.95 billion. During the same quarter last year, the company posted $6.10 EPS. Thermo Fisher Scientific's quarterly revenue was up 7.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th will be paid a $0.47 dividend. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.43. The ex-dividend date is Friday, March 13th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is presently 10.60%.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on TMO shares. Citigroup raised their target price on shares of Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a "buy" rating in a research report on Friday, January 30th. Barclays raised their target price on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an "overweight" rating in a research report on Friday, January 30th. Weiss Ratings reiterated a "hold (c)" rating on shares of Thermo Fisher Scientific in a research note on Wednesday, April 8th. Wells Fargo & Company set a $683.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Finally, TD Cowen cut their price target on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating for the company in a research note on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $632.50.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.